Cytotec
Executive Summary
Searle files supplemental NDA for misoprostil in the prevention of gastrointestinal ulcers caused by NSAIDs, based on results with 450 patients. The company's NDA for the prostaglandin product for the treatment of duodenal ulcers is still pending at FDA.
Searle files supplemental NDA for misoprostil in the prevention of
gastrointestinal ulcers caused by NSAIDs, based on results with 450
patients. The company's NDA for the prostaglandin product for the
treatment of duodenal ulcers is still pending at FDA. |